title: Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
authors.affiliation: Department of Dermatology, Venerology and Allergy, Allergie-Centrum Charité, Charité - Universitätsmedizin, Berlin, Germany.
authors.forename: Janine
authors.initials: J
authors.lastname: Gericke
authors.affiliation: Department of Dermatology, Venerology and Allergy, Allergie-Centrum Charité, Charité - Universitätsmedizin, Berlin, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Metz
authors.affiliation: Department of Dermatology, Venerology and Allergy, Allergie-Centrum Charité, Charité - Universitätsmedizin, Berlin, Germany.
authors.forename: Tatevik
authors.initials: T
authors.lastname: Ohanyan
authors.affiliation: Department of Dermatology, Venerology and Allergy, Allergie-Centrum Charité, Charité - Universitätsmedizin, Berlin, Germany.
authors.forename: Karsten
authors.initials: K
authors.lastname: Weller
authors.affiliation: Department of Dermatology, Venerology and Allergy, Allergie-Centrum Charité, Charité - Universitätsmedizin, Berlin, Germany.
authors.forename: Sabine
authors.initials: S
authors.lastname: Altrichter
authors.affiliation: Dermatological Department, University Hospital of Southern Denmark, Odense, Denmark; RefLab ApS, Copenhagen, Denmark; Institute of Immunology, National University of Copenhagen, Copenhagen, Denmark.
authors.forename: Per Stahl
authors.initials: PS
authors.lastname: Skov
authors.affiliation: RefLab ApS, Copenhagen, Denmark.
authors.forename: Sidsel
authors.initials: S
authors.lastname: Falkencrone
authors.affiliation: BioTeZ Berlin-Buch GmbH, Berlin, Germany.
authors.forename: Janko
authors.initials: J
authors.lastname: Brand
authors.affiliation: IPM Biotech GmbH, Hamburg, Germany.
authors.forename: Arno
authors.initials: A
authors.lastname: Kromminga
authors.affiliation: Department of Dermatology, Venerology and Allergy, Allergie-Centrum Charité, Charité - Universitätsmedizin, Berlin, Germany.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Hawro
authors.affiliation: Department of Dermatology, Venerology and Allergy, Allergie-Centrum Charité, Charité - Universitätsmedizin, Berlin, Germany.
authors.forename: Martin K
authors.initials: MK
authors.lastname: Church
authors.affiliation: Department of Dermatology, Venerology and Allergy, Allergie-Centrum Charité, Charité - Universitätsmedizin, Berlin, Germany. Electronic address: marcus.maurer@charite.de.
authors.forename: Marcus
authors.initials: M
authors.lastname: Maurer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000097:blood / Q000276:immunology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab / Q000627:therapeutic use*; D014581:Urticaria / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D055815:Young Adult
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D001323:Autoantibodies; D000069444:Omalizumab; D007073:Immunoglobulin E